| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medicine, The University of Chicago, Chicago, Illinois 60637
Elevated serum and tissue lipid stores are associated with skeletal muscle insulin resistance and diminished glucose-stimulated insulin secretion, the hallmarks of type 2 diabetes. We studied the effects of 6-wk treatment with the insulin sensitizer troglitazone on substrate storage and utilization in lean control and Zucker diabetic fatty (ZDF) rats. Troglitazone prevented development of diabetes and lowered serum triglycerides (TG) in ZDF rats. Soleus muscle glycogen and TG content were elevated twofold in untreated ZDF rats, and both were normalized by troglitazone to lean control levels (P < 0.05). Troglitazone also normalized insulin-stimulated glucose uptake as well as basal and insulin-stimulated glycogen synthesis, implying increased skeletal muscle glycogen turnover. The proportion of active pyruvate dehydrogenase (PDH) in soleus muscle was reduced in ZDF relative to lean control rat muscle (16 ± 2 vs. 21 ± 2%) but was restored by troglitazone treatment (30 ± 3%). Increased PDH activation was associated with a 70% increase in glucose oxidation. Muscle lipoprotein lipase activity was decreased by 35% in ZDF compared with lean control rats and was increased twofold by troglitazone. Palmitate oxidation and incorporation into TG were higher in ZDF relative to lean control rats but were unaffected by troglitazone treatment. Troglitazone decreased the incorporation of glucose into the acyl group of TG by 60% in ZDF rats. In summary, ZDF rats demonstrate increased skeletal muscle glycogen and TG stores, both of which were reduced by troglitazone treatment. Troglitazone appears to increase both glycogen and TG turnover in skeletal muscle. Normalization of PDH activity and decreased glucose incorporation into acyl TG may underlie the improvements in intracellular substrate utilization and energy stores, which lead to decreased serum TG and glucose.
insulin resistance; non-insulin-dependent diabetes mellitus; glucose metabolism; free fatty acid metabolism; thiazolidinedione
This article has been cited by other articles:
|
|
 |
|
  L. A. Lesniewski, A. J. Donato, B. J. Behnke, C. R. Woodman, M. H. Laughlin, C. A. Ray, and M. D. Delp Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1840 - H1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Simeone, L. Zhang, M. K. Treutelaar, L. Zhang, K. Graziano, C. D. Logsdon, and C. F. Burant Islet hypertrophy following pancreatic disruption of Smad4 signaling Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1305 - E1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chabowski, J. C. Chatham, N. N. Tandon, J. Calles-Escandon, J. F. C. Glatz, J. J. F. P. Luiken, and A. Bonen Fatty acid transport and FAT/CD36 are increased in red but not in white skeletal muscle of ZDF rats Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E675 - E682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Golfman, C. R. Wilson, S. Sharma, M. Burgmaier, M. E. Young, P. H. Guthrie, M. Van Arsdall, J. V. Adrogue, K. K. Brown, and H. Taegtmeyer Activation of PPAR{gamma} enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E328 - E336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al. PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1314 - H1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R Almon, D. C DuBois, J. Y Jin, and W. J Jusko Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle J. Endocrinol., January 1, 2005; 184(1): 219 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Jucker, T. R. Schaeffer, R. E. Haimbach, T. S. McIntosh, D. Chun, M. Mayer, D. H. Ohlstein, H. M. Davis, S. A. Smith, A. R. Cobitz, et al. Normalization of Skeletal Muscle Glycogen Synthesis and Glycolysis in Rosiglitazone-Treated Zucker Fatty Rats: An In Vivo Nuclear Magnetic Resonance Study Diabetes, July 1, 2002; 51(7): 2066 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Atkinson, S. E. Kelly, J. C. Russell, J. Bar-Tana, and G. D. Lopaschuk MEDICA 16 Inhibits Hepatic Acetyl-CoA Carboxylase and Reduces Plasma Triacylglycerol Levels in Insulin-Resistant JCR: LA-cp Rats Diabetes, May 1, 2002; 51(5): 1548 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Brunmair, F. Gras, S. Neschen, M. Roden, L. Wagner, W. Waldhausl, and C. Furnsinn Direct Thiazolidinedione Action on Isolated Rat Skeletal Muscle Fuel Handling Is Independent of Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Changes in Gene Expression Diabetes, October 1, 2001; 50(10): 2309 - 2315. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
